- Home
- NVEE vs SPRY Comparison
NVEE vs SPRY Comparison
Compare NVEE & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVEE
- SPRY
- Stock Information
- Founded
- NVEE 1949
- SPRY 2015
- Country
- NVEE United States
- SPRY United States
- Employees
- NVEE N/A
- SPRY N/A
- Industry
- NVEE Other Consumer Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- NVEE Consumer Discretionary
- SPRY Health Care
- Exchange
- NVEE Nasdaq
- SPRY Nasdaq
- Market Cap
- NVEE 1.0B
- SPRY 1.2B
- IPO Year
- NVEE 2013
- SPRY N/A
- Fundamental
- Price
- NVEE $19.34
- SPRY $13.44
- Analyst Decision
- NVEE Strong Buy
- SPRY Strong Buy
- Analyst Count
- NVEE 3
- SPRY 4
- Target Price
- NVEE $25.67
- SPRY $28.75
- AVG Volume (30 Days)
- NVEE 498.6K
- SPRY 1.2M
- Earning Date
- NVEE 05-01-2025
- SPRY 05-14-2025
- Dividend Yield
- NVEE N/A
- SPRY N/A
- EPS Growth
- NVEE N/A
- SPRY N/A
- EPS
- NVEE 0.45
- SPRY 0.08
- Revenue
- NVEE $962,752,000.00
- SPRY $89,149,000.00
- Revenue This Year
- NVEE $10.70
- SPRY $1.49
- Revenue Next Year
- NVEE $5.66
- SPRY $141.68
- P/E Ratio
- NVEE $43.18
- SPRY $168.31
- Revenue Growth
- NVEE 8.74
- SPRY 297063.34
- 52 Week Low
- NVEE $14.75
- SPRY $7.55
- 52 Week High
- NVEE $26.14
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- NVEE 65.09
- SPRY 46.69
- Support Level
- NVEE $18.14
- SPRY $13.06
- Resistance Level
- NVEE $19.08
- SPRY $15.06
- Average True Range (ATR)
- NVEE 0.78
- SPRY 0.67
- MACD
- NVEE 0.33
- SPRY -0.18
- Stochastic Oscillator
- NVEE 96.98
- SPRY 15.97
About NVEE NV5 Global Inc.
NV5 Global Inc is a provider of technology, conformity assessment, and consulting solutions to public and private sector clients in the infrastructure, utility services, construction, real estate, environmental, and geospatial markets, operating nationwide and abroad. The Company's clients include the U.S. Federal, state and local governments, and the private sector. The operating business segments are Infrastructure, Building, Technology & Sciences, and Geospatial Solutions. The maximum revenue derives from the infrastructure segment.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.